Cordlife Group (SGX:P8A) ROCE % : 1.60% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Cordlife Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cordlife Group's annualized ROCE % for the quarter that ended in Dec. 2023 was 1.60%.

Cordlife Group ROCE % Historical Data

The historical data trend for Cordlife Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cordlife Group ROCE % Chart

Cordlife Group Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

4.51

3.89

3.46

2.71

2.20

Cordlife Group Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															4.21	2.21	3.22	2.75	1.60

Cordlife Group ROCE % Calculation

Cordlife Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	4.526	/	( ( (227.995 - 20.888)	+	(228.456 - 24.326) )	/ 2 )
	=	4.526	/	( (207.107	+	204.13)	/ 2 )
	=	4.526	/	205.6185
	=	2.20 %

Cordlife Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	3.312	/	( ( (234.03 - 24.407)	+	(228.456 - 24.326) )	/ 2 )
	=	3.312	/	( ( 209.623	+	204.13 )	/ 2 )
	=	3.312	/	206.8765
	=	1.60 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Cordlife Group (SGX:P8A) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cordlife Group ROCE % Related Terms

Thank you for viewing the detailed overview of Cordlife Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cordlife Group (SGX:P8A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cordlife Group Ltd (SGX:P8A) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CLIFF:USA

Address

1 Yishun Industrial Street 1, Number 06-01/09, A'Posh Bizhub, Singapore, SGP, 768160

Website

https://www.cordlife.com

Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Cordlife has processing and storage facilities in six key markets across Asia, namely Singapore, Hong Kong, Malaysia, India, Indonesia, and the Philippines. The company has two segments - The Banking segment, comprises cord blood, cord lining, and cord tissue services. The Diagnostics segment comprises Metascreen, which is a non-invasive metabolic screening test specially designed for newborn babies, non-invasive prenatal testing service and Eyescreen, a paediatric eye-screening service.

Cordlife Group (SGX:P8A) Headlines

No Headlines